Monthly Archives: October 2024

As we celebrate Black History Month, we recognise the important contributions of Black colleagues across our sector. This month honours Black history, achievements and experiences, but it has also provided us a time to reflect and reaffirm our dedication to equality, diversity, and inclusion (EDI). Our Chief Executive Janet Morrison said: “At Community Pharmacy England, [...]

The post Honouring Black History Month and EDI appeared first on Community Pharmacy England.

A new Medicines and Healthcare products Regulatory Agency (MHRA) Drug Safety Update (Vol 18 Issue 3 October 2024) has been published and includes articles on: GLP-1 receptor agonists: reminder of the potential side effects and to be aware of the potential for misuse. Insulin pumps and continuous glucose monitoring (CGM) equipment: guidance for users on [...]

The post MHRA: Drug Safety Update: October 2024 appeared first on Community Pharmacy England.

Minister Stephen Kinnock recently responded to a Parliamentary Question regarding pharmacy reimbursement. In his response, he stated that pharmacies were allowed to retain £850m medicine margin in the year 2023/24. The pharmacy funding settlement for 2022/23 and 2023/24 included an uplift to the Drug Tariff, as £100m in excess margin earned by the sector in [...]

The post Clarification regarding retained margin in 2023/24 appeared first on Community Pharmacy England.

Drug alert number: EL (24)A/50 Date issued: 23 October 2024 Bristol Laboratories Ltd. are recalling one batch of Phenobarbital Bristol Labs 15mg Tablets as a precautionary measure due to the potential of contamination of small metallic particles within the tablets. PL 17907/0175 DMRC Number: DMRC-32910584 SNOMED Code:21039211000001106 Batch No Expiry Date Pack Size First Distributed [...]

The post MHRA Class 2 Medicines Recall: Phenobarbital Bristol Labs 15mg Tablets (Bristol Laboratories Ltd) appeared first on Community Pharmacy England.